CervoMed Inc. (CRVO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US15713L1098
CervoMed Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 4.01 m USD |
| Operating income | -28.29 m USD |
| EBIT | -28.30 m USD |
| Net income | -26.97 m USD |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
More stocks
- AMERICAN VANGUARD CORP (AVD)
- Metagenomi Therapeutics, Inc. (MGX)
- Xos, Inc. (XOS)
- Mono Next Public Company Limited (MONO.BK)
- ATLANTIC AMERICAN CORP (AAME)
- Tonix Pharmaceuticals Holding Corp. (TNXP)
- Lite Strategy, Inc. (LITS)
- Bio Essence Corp (BIOE)
- Scientist Home Future Health Ltd (SHFH)
- ConnectM Technology Solutions, Inc. (CNTM)
- OLD MARKET CAPITAL Corp (OMCC)
- HeartBeam, Inc. (BEAT)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.